Tumor progression by immune evasion in melanoma: Role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction

Cancer

Volumn 116, Issue 7, 2010, Pages 1623-1625

  Kashani Sabet, Mohammed ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BIOLOGICAL MARKER; INTERLEUKIN 10; TUMOR MARKER;

ANGIOGENESIS; ANTIGEN EXPRESSION; APOPTOSIS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CYTOKINE PRODUCTION; EDITORIAL; GENOME; HIGH RISK PATIENT; HUMAN; IMMUNOSURVEILLANCE; LYMPHANGIOGENESIS; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; IMMUNE EVASION; MELANOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950212222     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24909     Document Type: Editorial

References (11)

1. Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr Opin Oncol. 2005;17:167-171.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
3. Gajewski TF. Identifying and overcoming resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res. 2006;12:2326s-2330s.
4. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
5. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002;62:3581-3586.
6. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death 1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116:1757-1766.
7. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
8. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174-17179.
9. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
10. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056.
11. Kashani-Sabet M, Venna S, Nosrati M, et al. A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res. 2009;15:6987-6992.